Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Gynecology

Free Subscription Articles published in Lancet Retrieve available abstracts of 116 articles: HTML format

Single Articles

November 2026
1. BIGOT C
   Women with obstetric fistula in Somalia deserve better - Author's reply.
   Lancet. 2026;408:1940.
   PubMed    
   
   
   
2. NGONGO CJ, Artan A, Majinge P, Raassen TJIP, et al
   Women with obstetric fistula in Somalia deserve better.
   Lancet. 2026;408:1939-1940.
   PubMed    
   
   
   
3. KARRON RA, Krubiner CB, Faden RR
   Inclusion of pregnant and lactating women in the Tumaini vaccine efficacy trial: a landmark advance.
   Lancet. 2026 Nov 4:S0140-6736(26)02155-0. doi: 10.1016/S0140-6736(26)02155.
   PubMed    
   
   
   October 2026
4. LORUSSO D, Martin-Babau J, Backes F, Ginesta MPB, et al
   Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.
   Lancet. 2026 Oct 26:S0140-6736(26)02099-4. doi: 10.1016/S0140-6736(26)02099.
   PubMed     Abstract available
   
   
   
5. SLOMOVITZ BM, Zhu J, Yin R, Backes F, et al
   First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-co
   Lancet. 2026 Oct 26:S0140-6736(26)02095-7. doi: 10.1016/S0140-6736(26)02095.
   PubMed     Abstract available
   
   
   
6. ODERKERK TJ, Leemans JC, Beelen P, Herman MC, et al
   Endometrial ablation plus levonorgestrel-releasing intrauterine system versus endometrial ablation alone in women with heavy menstrual bleeding in The Netherlands (MIRA2): a multicentre, open-label, randomised, controlled, superiority trial.
   Lancet. 2026 Oct 21:S0140-6736(26)01536-9. doi: 10.1016/S0140-6736(26)01536.
   PubMed     Abstract available
   
   
   
7. LEMOS MJ, Carugno J
   Preserving the uterus: an effective dual therapy to avoid hysterectomy.
   Lancet. 2026 Oct 21:S0140-6736(26)01715-0. doi: 10.1016/S0140-6736(26)01715.
   PubMed    
   
   
   
8. CLIFFORD GM, Wei F
   WHO should adjust its cervical cancer plan - Authors' reply.
   Lancet. 2026;408:1550.
   PubMed    
   
   
   
9. SUBA EJ
   WHO should adjust its cervical cancer plan.
   Lancet. 2026;408:1549-1550.
   PubMed    
   
   
   September 2026
10. COLOMBO N, Zsiros E, Hasegawa K, Coleman RL, et al
    Platinum-resistant ovarian cancers: lessons from KEYNOTE-B96 - Authors' reply.
    Lancet. 2026;408:1091-1092.
    PubMed    
    
    
    
11. QUESADA S, Rodrigues M, Hardy AC, You B, et al
    Platinum-resistant ovarian cancers: lessons from KEYNOTE-B96.
    Lancet. 2026;408:1090-1091.
    PubMed    
    
    
    
12. WU R, Zachou G, van der Meulen J, Michael A, et al
    Unmasking inequity: emergency presentations in ovarian cancer care.
    Lancet. 2026;408:1088.
    PubMed    
    
    
    
13. MOORE KN, Ray-Coquard I
    Unmasking inequity: emergency presentations in ovarian cancer care - Authors' reply.
    Lancet. 2026;408:1088-1089.
    PubMed    
    
    
    
14. BRAZILE TL, Conrad N, Bergman L, Gnanaraj JP, et al
    Cardiovascular disease in pregnancy: physiology, global burden, risk stratification, and opportunities in care.
    Lancet. 2026;408:935-951.
    PubMed     Abstract available
    
    
    
15. PABON MA, Smith G, Sharma G, Catov J, et al
    Adverse pregnancy outcomes and long-term cardiovascular disease risk.
    Lancet. 2026;408:952-968.
    PubMed     Abstract available
    
    
    August 2026
16. WALKER MC, Murphy MSQ, Scremin Souza SC, Koi-Larbi K, et al
    Pre-eclampsia.
    Lancet. 2026;408:847-860.
    PubMed     Abstract available
    
    
    July 2026
17. SCHWARTZ L, Ahmed E, Palmero A, Ho CWL, et al
    Pregnancy as exclusion criterion in Ebola research: not again.
    Lancet. 2026 Jul 17:S0140-6736(26)01367-X. doi: 10.1016/S0140-6736(26)01367.
    PubMed    
    
    
    June 2026
18. PORTNOY A, Burger EA
    HPV vaccination and early declines in cervical cancer deaths.
    Lancet. 2026 Jun 17:S0140-6736(26)01024-X. doi: 10.1016/S0140-6736(26)01024.
    PubMed    
    
    
    
19. SASIENI P, Falcaro M
    Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data.
    Lancet. 2026 Jun 17:S0140-6736(26)00918-9. doi: 10.1016/S0140-6736(26)00918.
    PubMed     Abstract available
    
    
    May 2026
20. TEEDE HJ, Khomami MB, Morman R, Laven JSE, et al
    Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.
    Lancet. 2026 May 12:S0140-6736(26)00717-8. doi: 10.1016/S0140-6736(26)00717.
    PubMed     Abstract available
    
    
    
21. BRISSON M, Drolet M, Gingras G, Laprise JF, et al
    Substantial increases in cervical cancer inequalities worldwide without enhanced human papillomavirus vaccination and screening efforts: a global modelling study.
    Lancet. 2026;407:1726-1737.
    PubMed     Abstract available
    
    
    
22. 
    Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials.
    Lancet. 2026;407:1699-1711.
    PubMed     Abstract available
    
    
    
23. CLIFFORD GM
    HPV vaccine scale-up is key to curb rising cervical cancer inequalities.
    Lancet. 2026;407:1662-1663.
    PubMed    
    
    
    April 2026
24. THE LANCET
    Abortion: the possibilities of progress.
    Lancet. 2026;407:1483.
    PubMed    
    
    
    
25. COLOMBO N, Zsiros E, Parma G, Rulli E, et al
    Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
    Lancet. 2026 Apr 10:S0140-6736(26)00602-1. doi: 10.1016/S0140-6736(26)00602.
    PubMed     Abstract available
    
    
    
26. LORUSSO D, Gladieff L, O'Malley DM, Kim JW, et al
    Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.
    Lancet. 2026 Apr 10:S0140-6736(26)00462-9. doi: 10.1016/S0140-6736(26)00462.
    PubMed     Abstract available
    
    
    
27. BIGOT C
    Giving dignity back: obstetric fistula in Somalia.
    Lancet. 2026 Apr 2:S0140-6736(26)00658-6. doi: 10.1016/S0140-6736(26)00658.
    PubMed    
    
    
    March 2026
28. HUANG JY, Low FM, Kee MZL, Hopper LN, et al
    More equitable preconception health: paternal life course opportunities for better pregnancy, child, and family outcomes.
    Lancet. 2026 Mar 16:S0140-6736(26)00148-0. doi: 10.1016/S0140-6736(26)00148.
    PubMed     Abstract available
    
    
    
29. SCHOENAKER D, Hall J, Verbiest S, Nonterah EA, et al
    Measuring progress in pregnancy planning and preconception health.
    Lancet. 2026 Mar 16:S0140-6736(26)00192-3. doi: 10.1016/S0140-6736(26)00192.
    PubMed     Abstract available
    
    
    
30. CARLIN N
    Cancer in pregnancy: navigating two medical systems.
    Lancet. 2026 Mar 6:S0140-6736(26)00465-4. doi: 10.1016/S0140-6736(26)00465.
    PubMed    
    
    
    February 2026
31. LEJEUNE CL, Van Calsteren K, Baert T, Vandecaveye V, et al
    A multidisciplinary management approach to cervical cancer during pregnancy.
    Lancet. 2026 Feb 17:S0140-6736(26)00190-X. doi: 10.1016/S0140-6736(26)00190.
    PubMed    
    
    
    January 2026
32. RAY-COQUARD I, Wilson C, Moore K
    The Lancet Commission on Ovarian Cancer: towards equity-driven reform.
    Lancet. 2026 Jan 8:S0140-6736(25)02463-8. doi: 10.1016/S0140-6736(25)02463.
    PubMed    
    
    
    
33. ROBERTS I
    Uterine atony and anaemia in postpartum haemorrhage.
    Lancet. 2026;407:29.
    PubMed    
    
    
    
34. YUNAS I, Devall A, Coomarasamy A
    Uterine atony and anaemia in postpartum haemorrhage - Authors' reply.
    Lancet. 2026;407:29-30.
    PubMed    
    
    
    
35. MANSUKHANI R, Chaudhri R, Bello FA, Muganyizi P, et al
    Uterine atony and anaemia in postpartum haemorrhage.
    Lancet. 2026;407:28-29.
    PubMed    
    
    
    December 2025
36. NASH Z, Christmas M, Gronlund T, Hickey M, et al
    Top ten menopause research priorities.
    Lancet. 2025;404:2535-2536.
    PubMed    
    
    
    
37. UBOM AE, Oiwoh SO
    Fetal and maternal outcomes following mpox infection in pregnancy.
    Lancet. 2025 Dec 19:S0140-6736(25)02317-7. doi: 10.1016/S0140-6736(25)02317.
    PubMed    
    
    
    
38. VAKANIAKI EH, Barhishindi I, Mubiala A, Malembaka EB, et al
    Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study.
    Lancet. 2025 Dec 19:S0140-6736(25)02309-8. doi: 10.1016/S0140-6736(25)02309.
    PubMed     Abstract available
    
    
    
39. MOAYAD L, Mihan A, Peters SAE, Van Spall HGC, et al
    Inclusion of women who are pregnant, lactating, or of reproductive potential in clinical trials: health, ethical, and regulatory considerations.
    Lancet. 2025;406:2858-2864.
    PubMed     Abstract available
    
    
    
40. TONG S, Cluver CA, Walker SP
    Reducing term pre-eclampsia by 30%: is it possible?
    Lancet. 2025 Dec 4:S0140-6736(25)01672-1. doi: 10.1016/S0140-6736(25)01672.
    PubMed    
    
    
    
41. GOADSBY J, Syngelaki A, Magee LA, von Dadelszen P, et al
    Scheduled birth at term for the prevention of pre-eclampsia (PREVENT-PE): an open-label randomised controlled trial.
    Lancet. 2025 Dec 4:S0140-6736(25)01207-3. doi: 10.1016/S0140-6736(25)01207.
    PubMed     Abstract available
    
    
    November 2025
42. NANA M, Painter R, Williamson C, Nelson-Piercy C, et al
    Hyperemesis gravidarum.
    Lancet. 2025 Nov 13:S0140-6736(25)01454-0. doi: 10.1016/S0140-6736(25)01454.
    PubMed     Abstract available
    
    
    
43. ANDERSON DJ, Bearak JM, Grimstad FW, Palanee-Phillips T, et al
    Biomedical innovations in contraception: gaps, obstacles, and solutions for sexual and reproductive health.
    Lancet. 2025;406:2119-2132.
    PubMed     Abstract available
    
    
    October 2025
44. SURYAWANSHI H, Gemmell LC, Morgan S, Koustas G, et al
    First clinical pregnancy following AI-based microfluidic sperm detection and recovery in non-obstructive azoospermia.
    Lancet. 2025 Oct 31:S0140-6736(25)01623-X. doi: 10.1016/S0140-6736(25)01623.
    PubMed    
    
    
    
45. ALLEMANI C, Minicozzi P, Morawski B, Lima CA, et al
    Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39
    Lancet. 2025 Oct 22:S0140-6736(25)01383-2. doi: 10.1016/S0140-6736(25)01383.
    PubMed     Abstract available
    
    
    
46. BEKKER LG, Joseph Davey D, Saidi F
    Two for two: lenacapavir during pregnancy and lactation.
    Lancet. 2025;406:1560-1561.
    PubMed    
    
    
    August 2025
47. MCCORMACK M, Eminowicz G, Vaja S, Hackshaw A, et al
    INTERLACE: not a new standard for cervical cancer chemoradiation - Authors' reply.
    Lancet. 2025;406:807.
    PubMed    
    
    
    
48. PETRIC P, Lindegaard JC, Schmid MP, Jurgenliemk-Schulz I, et al
    INTERLACE: not a new standard for cervical cancer chemoradiation.
    Lancet. 2025;406:806-807.
    PubMed    
    
    
    
49. 
    Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
    Lancet. 2025;406:603-614.
    PubMed     Abstract available
    
    
    
50. LIU T, Lu D, Wu X
    Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial - Authors' reply.
    Lancet. 2025;406:446.
    PubMed    
    
    
    
51. CHENG C
    Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial.
    Lancet. 2025;406:445.
    PubMed    
    
    
    
52. HUANG L, We Y, Chen F
    Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial.
    Lancet. 2025;406:445-446.
    PubMed    
    
    
    July 2025
53. BRASIL P, Nielsen-Saines K, Guaraldo L, Fuller T, et al
    A decade later, what have we learned from the Zika epidemic in children with intrauterine exposure?
    Lancet. 2025 Jul 3:S0140-6736(25)00826-8. doi: 10.1016/S0140-6736(25)00826.
    PubMed     Abstract available
    
    
    June 2025
54. HARTER P, Marme F
    Targeting the glucocorticoid receptor in relapsed ovarian cancer: a new pathway and standard treatment option in ovarian cancer.
    Lancet. 2025;405:2180-2182.
    PubMed    
    
    
    
55. DE SMIT NS, de Lange ME, Boomsma MF, Huirne JAF, et al
    Current treatment for symptomatic uterine fibroids: available evidence and therapeutic dilemmas.
    Lancet. 2025 Jun 19:S0140-6736(25)00728-7. doi: 10.1016/S0140-6736(25)00728.
    PubMed     Abstract available
    
    
    
56. FERNANDEZ TURIENZO C, November L, Kamara M, Conteh O, et al
    Community-based mentoring to reduce maternal and perinatal mortality in adolescent pregnancies in Sierra Leone (2YoungLives): a pilot cluster-randomised controlled trial.
    Lancet. 2025 Jun 18:S0140-6736(25)00454-4. doi: 10.1016/S0140-6736(25)00454.
    PubMed     Abstract available
    
    
    
57. HODNETT E
    A community-based landmark trial to save the lives of pregnant adolescents and their newborns in sub-Saharan Africa.
    Lancet. 2025 Jun 18:S0140-6736(25)00731-7. doi: 10.1016/S0140-6736(25)00731.
    PubMed    
    
    
    
58. OLAWAIYE AB, Gladieff L, O'Malley DM, Kim JW, et al
    Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
    Lancet. 2025 Jun 2:S0140-6736(25)01040-2. doi: 10.1016/S0140-6736(25)01040.
    PubMed     Abstract available
    
    
    May 2025
59. SCHOENAKER D, Stephenson J, Chakrabarti S, Alloway L, et al
    Prioritising maternal health must include care before pregnancy.
    Lancet. 2025;405:1903.
    PubMed    
    
    
    
60. GARDOSI J, Ewington LJ, Booth K, Bick D, et al
    Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial.
    Lancet. 2025 May 1:S0140-6736(25)00162-X. doi: 10.1016/S0140-6736(25)00162.
    PubMed     Abstract available
    
    
    March 2025
61. LAUDANSKI P
    Natural or artificial menstrual cycle for frozen embryo transfer.
    Lancet. 2025;405:893-894.
    PubMed    
    
    
    
62. MAKAMA M, Vogel JP
    Atosiban and managing women in preterm labour.
    Lancet. 2025 Mar 3:S0140-6736(25)00402-7. doi: 10.1016/S0140-6736(25)00402.
    PubMed    
    
    
    February 2025
63. RAHIM MN, Williamson C, Kametas NA, Heneghan MA, et al
    Pregnancy and the liver.
    Lancet. 2025;405:498-513.
    PubMed     Abstract available
    
    
    
64. HUGHES H
    Endometriosis: an Australian perspective on encouraging change.
    Lancet. 2025;405:378-379.
    PubMed    
    
    
    
65. DANG L, Mi M, Qiao Y, Zhu L, et al
    Eliminating cervical cancer in the Tibetan Plateau.
    Lancet. 2025;405:375-376.
    PubMed    
    
    
    November 2024
66. LORUSSO D, Yamada K, Li K, Cerrotta A, et al
    Pembrolizumab for locally advanced cervical cancer - Authors' reply.
    Lancet. 2024;404:2051-2052.
    PubMed    
    
    
    
67. DONG B, Lu Y, Wang Y, Sun P, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2050.
    PubMed    
    
    
    
68. SCHMID MP, Petric P, Mahantshetty U, Kirisits C, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2050-2051.
    PubMed    
    
    
    
69. KAMRAVA M, Beriwal S
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2049.
    PubMed    
    
    
    
70. MURAKAMI N, Okonogi N, Terao Y, Shikama N, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2049-2050.
    PubMed    
    
    
    
71. 
    Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    PubMed     Abstract available
    
    
    October 2024
72. MCCORMACK M, Eminowicz G, Gallardo D, Diez P, et al
    Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
    Lancet. 2024;404:1525-1535.
    PubMed     Abstract available
    
    
    
73. DUSKA LR, Randall LM
    Progress in the treatment paradigms for locally advanced cervical cancer.
    Lancet. 2024;404:1494-1496.
    PubMed    
    
    
    
74. WU X, Sun Y, Yang H, Wang J, et al
    Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
    Lancet. 2024 Oct 15:S0140-6736(24)02135-4. doi: 10.1016/S0140-6736(24)02135.
    PubMed     Abstract available
    
    
    
75. SUN C, Ma D
    Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer.
    Lancet. 2024 Oct 15:S0140-6736(24)02196-2. doi: 10.1016/S0140-6736(24)02196.
    PubMed    
    
    
    
76. THE LANCET
    Endometriosis: addressing the roots of slow progress.
    Lancet. 2024;404:1279.
    PubMed    
    
    
    September 2024
77. SHARP G, Randhawa A, Fernando AN
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01710-0. doi: 10.1016/S0140-6736(24)01710.
    PubMed    
    
    
    
78. BROWN L, Hunter MS, Crandall CJ, Connors HJ, et al
    Reflections on The Lancet menopause Series - Authors' reply.
    Lancet. 2024 Sep 25:S0140-6736(24)01712-4. doi: 10.1016/S0140-6736(24)01712.
    PubMed    
    
    
    
79. STUCKEY BGA
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01709-4. doi: 10.1016/S0140-6736(24)01709.
    PubMed    
    
    
    
80. XIAO Y, Shen M, Chen X
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01711-2. doi: 10.1016/S0140-6736(24)01711.
    PubMed    
    
    
    
81. GENNIGENS C
    Hope emerging in the locally advanced cervical cancer landscape.
    Lancet. 2024 Sep 13:S0140-6736(24)01918-4. doi: 10.1016/S0140-6736(24)01918.
    PubMed    
    
    
    
82. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-
    Lancet. 2024 Sep 13:S0140-6736(24)01808-7. doi: 10.1016/S0140-6736(24)01808.
    PubMed     Abstract available
    
    
    August 2024
83. RYDELIUS J, Hognert H, Kopp-Kallner H, Brandell K, et al
    First dose of misoprostol administration at home or in hospital for medical abortion between 12-22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial.
    Lancet. 2024;404:864-873.
    PubMed     Abstract available
    
    
    
84. MOSESON H, Gerdts C
    Expanding access, reducing burdens, and improving person-centred care in abortion.
    Lancet. 2024;404:826-827.
    PubMed    
    
    
    
85. FIGUERAS F, Rial-Crestelo M, Gratacos E
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial - Authors' reply.
    Lancet. 2024;404:751-752.
    PubMed    
    
    
    
86. GILES-CLARK HJ, Rolnik DL, Hodges RJ, Skinner SM, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:750.
    PubMed    
    
    
    
87. BACON I, Hezelgrave NL, Cerdeira AS, Mylrea-Foley B, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:750-751.
    PubMed    
    
    
    
88. KAMIHARA Y, Nagase H, Ishikawa H
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:749-750.
    PubMed    
    
    
    
89. MEIJERINK L, Terstappen F, Depmann M, Bekker M, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:749.
    PubMed    
    
    
    
90. BORNSTEIN E, Vintzileos A
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:748-749.
    PubMed    
    
    
    
91. WEI F, Georges D, Man I, Baussano I, et al
    Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature.
    Lancet. 2024;404:435-444.
    PubMed     Abstract available
    
    
    
92. SCHIFFMAN M, de Sanjose S
    The rational design of cervical cancer prevention strategies.
    Lancet. 2024;404:406-407.
    PubMed    
    
    
    July 2024
93. ALVES L
    New abortion bill in Brazil sparks backlash.
    Lancet. 2024;404:17.
    PubMed    
    
    
    June 2024
94. HO VNA, Pham TD, Nguyen NT, Wang R, et al
    Livebirth rate after one frozen embryo transfer in ovulatory women starting with natural, modified natural, or artificial endometrial preparation in Viet Nam: an open-label randomised controlled trial.
    Lancet. 2024 Jun 26:S0140-6736(24)00756-6. doi: 10.1016/S0140-6736(24)00756.
    PubMed     Abstract available
    
    
    
95. JAFFE S
    US Supreme Court protects access to abortion medication.
    Lancet. 2024;403:2679-2680.
    PubMed    
    
    
    
96. SWEETING A, Hannah W, Backman H, Catalano P, et al
    Epidemiology and management of gestational diabetes.
    Lancet. 2024 Jun 18:S0140-6736(24)00825-0. doi: 10.1016/S0140-6736(24)00825.
    PubMed     Abstract available
    
    
    
97. HIVERT MF, Backman H, Benhalima K, Catalano P, et al
    Pathophysiology from preconception, during pregnancy, and beyond.
    Lancet. 2024 Jun 18:S0140-6736(24)00827-4. doi: 10.1016/S0140-6736(24)00827.
    PubMed     Abstract available
    
    
    May 2024
98. SAMARASINGHE SNS, Leca B, Alabdulkader S, Dimitriadis GK, et al
    Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
    Lancet. 2024 May 20:S0140-6736(24)00538-5. doi: 10.1016/S0140-6736(24)00538.
    PubMed     Abstract available
    
    
    
99. MORIN-PAPUNEN L
    Bariatric surgery in women with PCOS and obesity.
    Lancet. 2024 May 20:S0140-6736(24)00811-0. doi: 10.1016/S0140-6736(24)00811.
    PubMed    
    
    
    April 2024
100. STRAND TA, McCann A, Kvestad I, Chandyo RK, et al
     Vitamin B12 deficiency in pregnant women - Authors' reply.
     Lancet. 2024;403:1450.
     PubMed    
     
     
     
101. SEN S
     Vitamin B12 deficiency in pregnant women.
     Lancet. 2024;403:1449-1450.
     PubMed    
     
     
     March 2024
102. JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al
     Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
     Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255.
     PubMed     Abstract available
     
     
     
103. GAILLARD R
     Optimising gestational weight gain among pregnant women with obesity.
     Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470.
     PubMed    
     
     
     
104. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
     Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
     Lancet. 2024 Mar 20:S0140-6736(24)00317-9. doi: 10.1016/S0140-6736(24)00317.
     PubMed     Abstract available
     
     
     
105. TEWARI KS, Monk BJ
     Immunotherapy plus chemoradiotherapy in cervical cancer management.
     Lancet. 2024 Mar 20:S0140-6736(24)00468-9. doi: 10.1016/S0140-6736(24)00468.
     PubMed    
     
     
     
106. HEISLER M, Mitchell N, Arey W, Erenberg M, et al
     US abortion bans should not pre-empt the duty to provide life-saving abortion care to pregnant patients in medical emergencies.
     Lancet. 2024 Mar 19:S0140-6736(24)00551-8. doi: 10.1016/S0140-6736(24)00551.
     PubMed    
     
     
     
107. DADOUN S, Demmler-Harrison GJ, Ketwaroo P, Castro EC, et al
     Congenital toxoplasmosis of the brain caused by infection in late pregnancy.
     Lancet. 2024;403:1081-1082.
     PubMed    
     
     
     
108. MISHRA GD, Davies MC, Hillman S, Chung HF, et al
     Optimising health after early menopause.
     Lancet. 2024;403:958-968.
     PubMed     Abstract available
     
     
     
109. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
     Managing menopause after cancer.
     Lancet. 2024;403:984-996.
     PubMed     Abstract available
     
     
     
110. BROWN L, Hunter MS, Chen R, Crandall CJ, et al
     Promoting good mental health over the menopause transition.
     Lancet. 2024;403:969-983.
     PubMed     Abstract available
     
     
     
111. HICKEY M, LaCroix AZ, Doust J, Mishra GD, et al
     An empowerment model for managing menopause.
     Lancet. 2024;403:947-957.
     PubMed     Abstract available
     
     
     
112. HAWKES P, Scott J, Hickey M
     500 Strong: celebrating older women's bodies in menopause and beyond.
     Lancet. 2024;403:894-903.
     PubMed    
     
     
     
113. SAMARASEKERA U
     Martha Hickey: responding to the complexity of menopause.
     Lancet. 2024;403:893.
     PubMed    
     
     
     
114. THE LANCET
     Time for a balanced conversation about menopause.
     Lancet. 2024;403:877.
     PubMed    
     
     
     
115. NIELSEN OH, Gubatan JM, Kolho KL, Streett SE, et al
     Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation.
     Lancet. 2024 Mar 5:S0140-6736(24)00052-7. doi: 10.1016/S0140-6736(24)00052.
     PubMed     Abstract available
     
     
     
116. ZAROCOSTAS J
     Renewed calls to scale-up cervical cancer screening.
     Lancet. 2024;403:797.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum